The Science Behind Anti-Aging Please

HUMAN, TOPICAL. Leyden and colleagues presented results at the 60th annual meeting of the American Academy of Dermatology in 2002. A facial cream containing GHK-Cu applied for 12 weeks to the facial skin of 71 women with mild to advanced signs of photoaging increased skin density and thickness, reduced laxity, improved clarity, and reduced fine lines and the depth of wrinkles.

A companion thigh-skin study, also 12 weeks, set GHK-Cu against two established actives. Collagen production improved in 70 percent of the women treated with GHK-Cu, compared with 50 percent of women treated with a vitamin C cream and 40 percent treated with retinoic acid. That figure is a responder rate - the proportion of women in whom collagen production improved - and on it the copper peptide came out ahead of both comparators, including retinoic acid.

WHAT GHK IS. GHK is a naturally occurring human tripeptide, glycyl-L-histidyl-L-lysine, originally isolated from human plasma. The standing review is Pickart L, Margolina A 2018, International Journal of Molecular Sciences 19(7):1987. It reports plasma GHK of roughly 200 ng/mL at age 20 falling to about 80 ng/mL by age 60 - that decline is the stated rationale for topical replacement - and it states directly that GHK-Cu penetrates the stratum corneum, which is what makes it active in cosmetic formulations.

WHAT GHK DOES IN TISSUE. The review documents that GHK stimulates blood vessel and nerve outgrowth, increases synthesis of collagen, elastin and glycosaminoglycans, and supports dermal fibroblast function. Tissue repair effects have been demonstrated in skin, lung connective tissue, bone, liver and stomach lining. The 2018 paper's specific contribution was gene expression analysis indicating that GHK modulates a very large share of human genes, including shifting expression patterns associated with tissue damage back toward a healthier profile.

TOPICAL, HUMAN - and a genuinely well-designed trial. Beitner H 2003, British Journal of Dermatology 149(4):841-849. Randomized, placebo-controlled, double-blind, split-face design. 33 women, mean age 54.4 years. After randomisation, one half of the face was treated twice daily for 12 weeks with a cream containing 5 percent alpha-lipoic acid, the other half with an identical control cream.

Four independent assessment methods were used and all four showed statistically significant improvement on the lipoic acid-treated half. Laser profilometry showed an average decrease in skin roughness of 50.8 percent (range 44.9 to 54.0) on the lipoic acid side, versus 40.7 percent (32.4 to 48.7) on the vehicle-treated half, p<0.001.

The split-face design is the real strength here: each woman served as her own control, which removes between-subject variation in skin type, sun exposure and ageing rate. That is a stronger internal control than most parallel-group cosmetic trials achieve, and it is the reason this result carries weight.

WHAT ALPHA-LIPOIC ACID IS. Alpha-lipoic acid, also called thioctic acid, is a dithiol compound and an essential cofactor for mitochondrial dehydrogenase complexes. It is unusual among antioxidants in being both water- and fat-soluble, which is why it is described as amphiphilic and why it can act in the aqueous cytosol and in lipid membranes at the same time. It also regenerates other antioxidants, including vitamins C and E and glutathione, which is a specific reason to formulate it alongside vitamin E.

TOPICAL, HUMAN. Farris P et al. 2014, Journal of Drugs in Dermatology 13(12):1467-1472. A nighttime topical antioxidant containing 1 percent trans-resveratrol, 0.5 percent baicalin and 1 percent vitamin E was applied for 12 weeks by 55 women aged 40 to 60 with mild to moderately photodamaged skin.

Results: statistically significant improvement over baseline in fine lines and wrinkles, skin firmness, elasticity, laxity, hyperpigmentation, radiance and tactile roughness. Improvements were noted as early as week 4. Ultrasound measurement of the periorbital area showed an average 18.9 percent improvement in dermal thickness, indicating dermal remodelling. In a subset of 10 women, gene expression of the skin biomarkers COL1A1, COL3A1, PRKAA1, SOD, VEGFA and HO-1 increased significantly, which lines up with the clinical measurements. That combination of a visible clinical result and a matching change in collagen gene expression is what makes this trial worth citing.

MORE RECENT WORK. A 2025 randomized, placebo-controlled 8-week trial of trans-resveratrol in healthy adult females over 40, published in Frontiers in Aging, reported reductions in visible signs of skin ageing. A separate placebo-controlled, double-blind study evaluated a resveratrol-procyanidin blend for nutraceutical antiaging efficacy.

WHAT RESVERATROL IS. Resveratrol is a stilbenoid polyphenol found in grape skin, red wine and Japanese knotweed. In skin it acts as a lipid- and aqueous-phase antioxidant and is described as a sirtuin-1 activator. Its dermatological interest rests on antioxidant capacity and on effects on collagen gene expression.

Astaxanthin is a xanthophyll carotenoid, most commonly sourced from the microalga Haematococcus pluvialis. Its long conjugated polyene chain terminating in hydroxyl and keto groups allows it to span a lipid bilayer with the polar ends anchored at both membrane surfaces, which is the structural basis for its antioxidant activity in membranes - a mechanism no other antioxidant in this formula reproduces.

HUMAN, CONTROLLED. Tominaga K, Hongo N, Karato M, Yamashita E 2012, 'Cosmetic benefits of astaxanthin on human subjects', Acta Biochimica Polonica 59(1):43-47, reported two studies.

The controlled one was randomized, double-blind and placebo-controlled: 36 healthy male subjects, 6 weeks, ORAL astaxanthin at 6 mg per day. Crow's feet wrinkle, elasticity and transepidermal water loss improved.

The second was an open-label study in 30 healthy female subjects over 8 weeks, combining 6 mg per day of ORAL astaxanthin with 2 mL per day of a TOPICAL 78.9 micromolar solution. Improvements were observed in crow's feet wrinkle at week 8, age spot size on the cheek at week 8, elasticity at crow's feet at week 8, skin texture on the cheek at week 4, moisture content of the corneocyte layer at week 8 in 10 dry-skin subjects, and corneocyte condition at week 8. Because both routes were given at once, the study describes the combination rather than either route alone.

Alpha-tocopherol is the principal lipid-soluble antioxidant of human skin. It is physiologically present in the stratum corneum and in sebum, where it terminates lipid peroxidation chain reactions in cell membranes.

MEASURED IN HUMAN SKIN. Thiele JJ and colleagues 1998, Journal of Investigative Dermatology: solar-simulated ultraviolet exposure BELOW the erythema threshold - that is, a dose that does not even visibly redden skin - depleted stratum corneum alpha-tocopherol by almost 50 percent. Vitamin E depletion by UV is a measurable, well-characterised physiological event, not a marketing premise, and it is regenerated in skin by vitamin C and by alpha-lipoic acid, which is a concrete reason those actives are formulated together.

TOPICAL, HUMAN. Farris P et al. 2014, Journal of Drugs in Dermatology 13(12):1467-1472: a nighttime topical containing 1 percent trans-resveratrol, 0.5 percent baicalin and 1 percent vitamin E, applied for 12 weeks by 55 women aged 40 to 60 with mild to moderately photodamaged skin. It produced significant improvement over baseline in fine lines and wrinkles, firmness, elasticity, laxity, hyperpigmentation, radiance and tactile roughness, with an average 18.9 percent improvement in periorbital dermal thickness on ultrasound.

ITS ROLE IN THIS FORMULA. Vitamin E is here as a formulation antioxidant with a specific job. Astaxanthin, coenzyme Q10, trans-resveratrol and bakuchiol are all oxidation-sensitive, and tocopherol protects them as well as protecting skin surface lipids. That is what 3.0 mg is doing, and it is a defined function rather than a decorative one.

Bakuchiol is a meroterpene phenol from the seeds of Psoralea corylifolia. It bears no structural resemblance to retinoids, yet behaves like one functionally - and unusually for a botanical cosmetic active, it has been tested head to head against retinol in a randomized double-blind trial.

THE HEAD-TO-HEAD TRIAL. Dhaliwal S, Rybak I, Ellis SR, et al. 2019, British Journal of Dermatology 180(2):289-296. Prospective, randomized, double-blind, 12 weeks, 44 patients. One arm applied bakuchiol 0.5 percent cream twice daily; the other applied retinol 0.5 percent cream once daily. A facial photographic and analytical imaging system captured and analysed high-resolution photographs at weeks 0, 4, 8 and 12.

Results: both bakuchiol and retinol significantly decreased wrinkle surface area and hyperpigmentation, with no statistically significant difference between the two compounds. Effects were most marked after the full 12 weeks. Tolerability separated them clearly - retinol users reported significantly more facial skin scaling and stinging. At week 12, 59 percent of the bakuchiol group showed improvement in hyperpigmentation versus 44 percent of the retinol group. The authors concluded that bakuchiol is comparable with retinol in improving photoageing and is better tolerated.

MECHANISM. Chaudhuri RK, Bojanowski K 2014, International Journal of Cosmetic Science 36(3):221-230. Comparative gene expression profiling of bakuchiol and retinol in the EpiDerm FT full-thickness skin substitute model. Volcano plots showed great overall similarity between the two compounds' effects on the gene expression profile despite the absence of structural similarity. Upregulation of type I and type IV collagen was confirmed in the DNA microarray study, stimulation of type III collagen was shown in the mature fibroblast model, and aquaporin 3 expression was analysed by ELISA and histochemistry in human dermal fibroblasts and EpiDerm FT substitutes.

A botanical active matching the dermatological reference standard on both wrinkle surface area and hyperpigmentation, in a double-blind randomized design, and beating it on tolerability, is a rare result in this category.

Coenzyme Q10, ubiquinone, is an endogenous component of the mitochondrial electron transport chain and a lipid-phase antioxidant. Skin levels decline with age and are depleted by ultraviolet exposure, which is the basis for topical replacement.

TOPICAL, HUMAN - and this study answers the arrival question directly, which is rare for any cosmetic active. Knott A, Achterberg V, Smuda C, et al. 2015, 'Topical treatment with coenzyme Q10-containing formulas improves skin's Q10 level and provides antioxidative effects', BioFactors 41(6):383-390.

This work did not only measure a cosmetic outcome, it measured whether the molecule arrived. After topical application, ubiquinone levels in the deeper layers of the EPIDERMIS were significantly augmented, indicating effective supplementation. Ubiquinol levels rose concurrently, which the authors interpreted as metabolic conversion of ubiquinone driven by increased energy metabolism. Incubating cultured human keratinocytes with Q10 concentrations equivalent to those measured in treated skin produced a significant augmentation of energy metabolism - so the concentrations actually reached in skin were shown to be biologically active concentrations. In stressed skin, topical Q10 reduced free radicals and increased antioxidant capacity, and a reduction in wrinkle depth following application was also reported.

Most actives are argued for on mechanism and inferred delivery. Q10 has been measured in the tissue after topical application, by direct quantification of both ubiquinone and its reduced form.